{"id":5858,"date":"2025-05-08T14:39:47","date_gmt":"2025-05-08T14:39:47","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=poster&#038;p=5858"},"modified":"2025-10-15T06:34:09","modified_gmt":"2025-10-15T06:34:09","slug":"duplex-proteinuria-remission-fsgs","status":"publish","type":"poster","link":"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/duplex-proteinuria-remission-fsgs\/","title":{"rendered":"Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)"},"content":{"rendered":"<section class=\"o-hero-section o-hero--banner o-hero--blue o-hero--cropped\">\n        <div class=\"container\">\n        <div class=\"m-hero-inner m-hero-inner--post\">\n            <div class=\"m-breadcrumb\">\n                <nav class=\"breadcrumbs\" aria-label=\"breadcrumb\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span><\/span><\/nav>            <\/div>\n            <h1 class=\"a-heading a-heading--h1 h-white\">Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)<\/h1>                    <\/div>\n    <\/div>\n<\/section>\n\n\n\n\r\n\t<section style=\"padding-top:0px;margin-top:calc(-180px * var(--scale));\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div class=\"info-block info-block-publication search__container-publication search__container\">\n\t<div class=\"info-block-top\">\n\t\t<div>\n\t\t\t\t\t\t\t<div class=\"info-block-type\"><i class=\"icon2-journal\" aria-hidden=\"true\"><\/i> Poster<\/div>\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"info-block-type\">\n\t\t\t\t\t<i class=\"icon2-calendar\" aria-hidden=\"true\"><\/i> Published on April 10, 2025\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics:<\/p>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">FSGS<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t<div class=\"info-block-bottom\">\n\t\t\t\t\t\t<div class=\"info-block-box\">\n\t\t\t\t\tContributors<br \/><span>Tumlin J, Tesar V, Trimarchi H et al.<\/span><br \/><br \/><br \/>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"info-block-box\">\n\t\t\t\t\tPresented at: <br \/><span>NKF Spring Clinical Meetings 2025<\/span><br \/><br \/><br \/>\n\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/04\/NKF2025_Poster_DUPLEX-FSGS-Thresholds.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"btn btn-outline\">View poster<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n\t\t<div class=\"info-block-share\">\n\t\t\tShare: \n\t\t\t<span>\n\t\t\t\t\t<a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fduplex-proteinuria-remission-fsgs%2F&#038;text=Patients+in+DUPLEX+Achieved+Partial+or+Complete+Remission+of+Proteinuria+Earlier+and+More+Often+With+Sparsentan+vs+Irbesartan%3A+Implications+for+Slowing+Progression+to+Kidney+Failure+in+Focal+Segmental+Glomerulosclerosis+%28FSGS%29\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-x\" aria-label=\"Share on Twitter\"><\/a> \n\t<a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fduplex-proteinuria-remission-fsgs%2F&#038;title=Patients+in+DUPLEX+Achieved+Partial+or+Complete+Remission+of+Proteinuria+Earlier+and+More+Often+With+Sparsentan+vs+Irbesartan%3A+Implications+for+Slowing+Progression+to+Kidney+Failure+in+Focal+Segmental+Glomerulosclerosis+%28FSGS%29\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-linkedin-2\" aria-label=\"Share on LinkedIn\"><\/a> \n\t<a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fduplex-proteinuria-remission-fsgs%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon-facebook\" aria-label=\"Share on Facebook\"><\/a> \n\t<a href=\"mailto:?subject=Patients%20in%20DUPLEX%20Achieved%20Partial%20or%20Complete%20Remission%20of%20Proteinuria%20Earlier%20and%20More%20Often%20With%20Sparsentan%20vs%20Irbesartan%3A%20Implications%20for%20Slowing%20Progression%20to%20Kidney%20Failure%20in%20Focal%20Segmental%20Glomerulosclerosis%20%28FSGS%29&#038;body=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fduplex-proteinuria-remission-fsgs%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-email-2\" aria-label=\"Share via Email\"><\/a>\n\t\t\t<\/span>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<h2 class=\"wp-block-heading has-text-align-center has-heading-4-font-size\" id=\"h-about-the-research\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">About the research<\/mark><\/span><\/h2>\n\n\n\n<div class=\"pdf-block\">\n\t\t\t\t<iframe src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/NKF2025_Presentation_DUPLEX-FSGS-Thresholds.pdf\" frameborder=\"0\"><\/iframe>\n\t\t<div class=\"pdf-block--buttons\">\n\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/NKF2025_Presentation_DUPLEX-FSGS-Thresholds.pdf\" class=\"btn\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"View\">View<\/a>\n\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/NKF2025_Presentation_DUPLEX-FSGS-Thresholds.pdf\" class=\"btn btn-outline\" download aria-label=\"Download\">Download<\/a>\n\t<\/div>\n<\/div>\n\n\n<h3 class=\"wp-block-heading has-text-align-center has-heading-4-font-size\" id=\"h-summary\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">Summary<\/mark><\/span><\/h3>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">Background<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><ul>\n<li>Focal segmental glomerulosclerosis (FSGS) is a rare, progressive kidney condition defined by a histological pattern of glomerular and podocyte injury<sup>1-3<\/sup><\/li>\n<li>It is associated with a high symptom, patient, and financial burden, including a substantial risk of kidney failure<sup>1,4-8<\/sup><\/li>\n<li>There are no FDA-approved therapies for FSGS, highlighting an unmet need for safe and effective treatments<sup>1,9<\/sup><\/li>\n<li>PARASOL identified <a href=\"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/\" target=\"_blank\" rel=\"noopener\">proteinuria as a biologically plausible and clinically meaningful endpoint<\/a>, with lower proteinuria strongly associated with reduced kidney failure risk<sup>1,10<\/sup><\/li>\n<li>Sparsentan is a novel, non-immunosuppressive <mark class=\"has-inline-color has-teal-color\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/protective-mechanism-sparsentan-chronic-kidney-disease-models\/\" target=\"_blank\" rel=\"noreferrer noopener\">Dual Endothelin Angiotensin Receptor Antagonist (DEARA)<\/a> <\/mark>that led to rapid and sustained proteinuria reductions in patients with FSGS in the <mark class=\"has-inline-color has-teal-color\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/Sparsentan-Versus-Irbesartan-in-Focal-Segmental-Glomerulosclerosis\/\" target=\"_blank\" rel=\"noreferrer noopener\">phase 3 DUPLEX trial<\/a> <\/mark>and <mark class=\"has-inline-color has-teal-color\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-irbesartan-fsgs-duet-trial-design\/\" target=\"_blank\" rel=\"noreferrer noopener\">phase 2 DUET study<\/a> <\/mark>compared to maximum labeled dose irbesartan<sup>1,11-15<\/sup><\/li>\n<li>Sparsentan was well-tolerated and has a similar safety profile to irbesartan<sup>12,15<\/sup><\/li>\n<\/ul>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-aim\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\">Aim<\/span><\/mark><\/h4>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><br>To investigate the impact of sparsentan 800 mg\/day vs irbesartan 300 mg\/day on partial remission (urine protein-creatinine ratio [UPCR] \u22641.5 g\/g and &gt;40% reduction from baseline) or complete remission (CR) (&lt;0.3 g\/g) of proteinuria and the effect of achieving these targets on progression to kidney failure in DUPLEX<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-1.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"896\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-1.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-1.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-1-300x105.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-1-1024x358.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-1-768x269.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-1-1536x538.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-1-2048x717.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-1-290x102.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\"><strong>Figure. DUPLEX study design<\/strong><\/mark><br><br><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>Analyses by treatment arm evaluated the proportion of patients achieving partial remission or CR of proteinuria at any time through 108 weeks<br><br>Pooled analyses using data from both treatment arms evaluated rates of progression to kidney failure in patients who achieved vs those who did not achieve low proteinuria<\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"resources\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Resources<\/mark><\/span><\/h5>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block feature-block--right\">\n\t\t\t\t\t\t\t<div class=\"m-card\">\n\t\t\t\t\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1440\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria_header-scaled.webp\" class=\"a-img\" alt=\"Explore the DUPLEX visual abstract\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria_header-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria_header-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria_header-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria_header-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria_header-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria_header-2048x1152.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria_header-290x163.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"m-card__info\">\n\t\t\t\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag a-tag--blue\">Downloadable Resource<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t\t\t\t\t<div class=\"m-card__text\">\n\t\t\t\t\t\t\t\t<h4 class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\t\t\t\t\tExplore the DUPLEX visual abstract\t\t\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/04\/NKF2025_Visual-abstract_DUPLEX-FSGS-Thresholds.pdf\" target=\"_blank\" rel=\"noopener\" class=\"a-btn a-btn--secondary--blue\">\n\t\t\t\t\t\t\t\t\t\t<span>View<\/span>\n\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"m-card\">\n\t\t\t\t\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header.png\" class=\"a-img\" alt=\"Explore the DUPLEX infographic\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header-290x163.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"m-card__info\">\n\t\t\t\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag a-tag--blue\">Downloadable Resource<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t\t\t\t\t<div class=\"m-card__text\">\n\t\t\t\t\t\t\t\t<h4 class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\t\t\t\t\tExplore the DUPLEX infographic\t\t\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/NKF2025-DUPLEX-infographic.pdf\" target=\"_blank\" rel=\"noopener\" class=\"a-btn a-btn--secondary--blue\">\n\t\t\t\t\t\t\t\t\t\t<span>View<\/span>\n\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-key-findings\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Key findings<\/mark><\/span><\/h5>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Patients achieved partial remission of proteinuria earlier and more often with sparsentan vs maximum labeled dose irbesartan<sup>1<\/sup><br><br>Findings demonstrated a 1.5-fold higher rate of partial remission with sparsentan vs maximum labeled dose irbesartan over 108 weeks<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-2.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1440\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-2.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-2.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-2-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-2-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-2-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-2-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-2-2048x1152.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-2-290x163.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">Figure. Probability of achieving partial remission<sup>\u2020<\/sup> of proteinuria through 108 weeks<sup>1<\/sup><\/mark><\/strong><br><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>The rate of partial remission<sup>\u2020<\/sup> of proteinuria at 108 weeks was 64.7% (119\/184) with sparsentan vs. 43.9% (82\/187) with irbesartan (Relative risk: 1.48, 95% CI: 1.23 to 1.78)<sup>1<\/sup><br><\/p>\n\n\n\n<p><sup>*<\/sup>P value generated from a stratified Cox proportional hazards model with treatment and baseline log (UPCR) as covariates, stratified by randomization stratification factors<sup>1<\/sup><br><\/p>\n\n\n\n<p><sup>\u2020<\/sup>UPCR \u22641.5 g\/g and &gt;40% reduction from baseline (also FSGS partial remission endpoint [FPRE])<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Patients achieved CR of proteinuria earlier and more often with sparsentan vs maximum labeled dose irbesartan<sup>1<\/sup><br><br>Findings demonstrated a 2.5-fold higher rate of complete remission with sparsentan vs maximum labeled dose irbesartan over 108 weeks<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/2.5-fold-CR_figure-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1440\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/2.5-fold-CR_figure-scaled.webp\" class=\"attachment-full size-full\" alt=\"Probability of achieving complete remission of proteinuria through 108 weeks\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/2.5-fold-CR_figure-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/2.5-fold-CR_figure-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/2.5-fold-CR_figure-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/2.5-fold-CR_figure-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/2.5-fold-CR_figure-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/2.5-fold-CR_figure-2048x1152.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/2.5-fold-CR_figure-290x163.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">Figure. Probability of achieving complete remission<sup>\u2020<\/sup> of proteinuria through 108 weeks<sup>1<\/sup><\/mark><\/strong><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>The rate of CR of proteinuria at 108 weeks was 18.5% (34\/184) with sparsentan vs 7.5% (14\/187) with irbesartan (Relative risk: 2.47, 95% CI: 1.37 to 4.45)<sup>1<\/sup><\/p>\n\n\n\n<p><br><sup>*<\/sup>P value generated from a stratified Cox proportional hazards model with treatment and baseline log (UPCR) as covariates, stratified by randomization stratification factors<sup>1<\/sup><\/p>\n\n\n\n<p><br><sup>\u2020<\/sup>UPCR &lt;0.3 g\/g<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Read more about sparsentan achieving <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span style=\"text-decoration: underline;\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/meetings-events\/era-congress-2025\/#duplex-low-proteinuria\" target=\"_blank\" rel=\"noreferrer noopener\">proteinuria reduction across several low proteinuria thresholds in a DUPLEX<\/a><\/span> <\/mark><em>post hoc<\/em> analysis<\/p>\n\n\n\n<p style=\"padding-bottom:calc(20px * var(--scale))\"><br>Patients who achieved low proteinuria were less likely to reach kidney failure vs those who did not, irrespective of treatment arm<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer paragraph-border\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-4.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1440\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-4.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-4.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-4-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-4-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-4-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-4-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-4-2048x1152.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-4-290x163.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><br><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">Figure. Probability of reaching kidney failure through 108 weeks<\/mark><\/strong><sup><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">\u20201<\/mark><\/strong><\/sup><br><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>Kidney failure occurred in 3.0% (6\/201) of patients who achieved partial remission<sup>\u2021<\/sup> of proteinuria vs 15.9% (27\/170) of those who did not (Relative risk: 0.33, 95% CI: 0.11 to 0.95)<sup>1<\/sup><br><\/p>\n\n\n\n<p>Kidney failure occurred in 2.1% (1\/48) of patients who achieved CR<sup>\u00a7<\/sup> of proteinuria vs 9.9% (32\/323) of those who did not (Relative risk: 0.23, 95% CI: 0.03 to 1.85)<sup>1<\/sup><br><\/p>\n\n\n\n<p><sup>*<\/sup>Confirmed estimated glomerular filtration rate (eGFR) of &lt;15 mL\/min\/1.73 m<sup>2<\/sup> or kidney replacement therapy<sup>1<\/sup><\/p>\n\n\n\n<p><sup>\u2020<\/sup>Results from <em>post hoc<\/em> analyses using pooled data irrespective of treatment arm<sup>1<\/sup><\/p>\n\n\n\n<p><sup>\u2021<\/sup>UPCR \u22641.5 g\/g and &gt;40% reduction from baseline (also FPRE)<sup>1<\/sup><br><\/p>\n\n\n\n<p><sup>\u00a7<\/sup>UPCR &lt;0.3 g\/g<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Sparsentan 800 mg\/day was well tolerated with a safety profile comparable to that of irbesartan<sup>1<\/sup><br><br>The most common treatment emergent adverse events (TEAEs) (\u226515% of patients in any group) included<sup>1<\/sup>:<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>COVID-19*<\/li>\n\n\n\n<li>Hyperkalemia<\/li>\n\n\n\n<li>Peripheral edema<\/li>\n\n\n\n<li>Hypotension<\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-5.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"888\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-5.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-5.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-5-300x104.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-5-1024x355.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-5-768x266.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-5-1536x533.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-5-2048x710.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/MCE1359-Travere-NKF-2025-Summary-Pages-V00-01-20250507-Figure-5-290x101.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><br><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">Table. Adverse events<sup>1<\/sup><\/mark><\/strong><br><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>TEAEs were experienced by 93% (172\/184) of patients with sparsentan and 93% (174\/187) of patients with irbesartan<sup>1<\/sup><\/p>\n\n\n\n<p><br>Serious TEAEs were experienced by 37% (68\/184) of patients with sparsentan and 44% (82\/187) of patients with irbesartan<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-conclusions\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Conclusions<\/mark><\/span><\/h5>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>In the DUPLEX study, patients with FSGS experienced rapid and sustained reduction in proteinuria with sparsentan compared to maximum labeled dose irbesartan<sup>1<\/sup><\/p>\n\n\n\n<p><br>Partial and complete remission was achieved earlier and more often with sparsentan<sup>1<\/sup><\/p>\n\n\n\n<p><br>Those who experienced low proteinuria had a lower risk of kidney failure<sup>1<\/sup><\/p>\n\n\n\n<p><br>Sparsentan 800 mg\/day was generally well tolerated over 108 weeks of treatment<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"newsletter\">\n\t<div class=\"newsletter-icon\">\n\t\t<span class=\"icon2-newsletter\"><\/span>\n\t<\/div>\n\t<div class=\"newsletter-text\">\n\t\t<p><strong>Sign up<\/strong> to receive scientific updates<br \/>\nfor healthcare professionals<br \/>\nfrom Travere Therapeutics.<\/p>\n\t<\/div>\n\t<div class=\"newsletter-form\">\n\t\t<script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\nvar gform;gform||(document.addEventListener(\"gform_main_scripts_loaded\",function(){gform.scriptsLoaded=!0}),document.addEventListener(\"gform\/theme\/scripts_loaded\",function(){gform.themeScriptsLoaded=!0}),window.addEventListener(\"DOMContentLoaded\",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,themeScriptsLoaded:!1,isFormEditor:()=>\"function\"==typeof InitializeEditor,callIfLoaded:function(o){return!(!gform.domLoaded||!gform.scriptsLoaded||!gform.themeScriptsLoaded&&!gform.isFormEditor()||(gform.isFormEditor()&&console.warn(\"The use of gform.initializeOnLoaded() is deprecated in the form editor context and will be removed in Gravity Forms 3.1.\"),o(),0))},initializeOnLoaded:function(o){gform.callIfLoaded(o)||(document.addEventListener(\"gform_main_scripts_loaded\",()=>{gform.scriptsLoaded=!0,gform.callIfLoaded(o)}),document.addEventListener(\"gform\/theme\/scripts_loaded\",()=>{gform.themeScriptsLoaded=!0,gform.callIfLoaded(o)}),window.addEventListener(\"DOMContentLoaded\",()=>{gform.domLoaded=!0,gform.callIfLoaded(o)}))},hooks:{action:{},filter:{}},addAction:function(o,r,e,t){gform.addHook(\"action\",o,r,e,t)},addFilter:function(o,r,e,t){gform.addHook(\"filter\",o,r,e,t)},doAction:function(o){gform.doHook(\"action\",o,arguments)},applyFilters:function(o){return gform.doHook(\"filter\",o,arguments)},removeAction:function(o,r){gform.removeHook(\"action\",o,r)},removeFilter:function(o,r,e){gform.removeHook(\"filter\",o,r,e)},addHook:function(o,r,e,t,n){null==gform.hooks[o][r]&&(gform.hooks[o][r]=[]);var d=gform.hooks[o][r];null==n&&(n=r+\"_\"+d.length),gform.hooks[o][r].push({tag:n,callable:e,priority:t=null==t?10:t})},doHook:function(r,o,e){var t;if(e=Array.prototype.slice.call(e,1),null!=gform.hooks[r][o]&&((o=gform.hooks[r][o]).sort(function(o,r){return o.priority-r.priority}),o.forEach(function(o){\"function\"!=typeof(t=o.callable)&&(t=window[t]),\"action\"==r?t.apply(null,e):e[0]=t.apply(null,e)})),\"filter\"==r)return e[0]},removeHook:function(o,r,t,n){var e;null!=gform.hooks[o][r]&&(e=(e=gform.hooks[o][r]).filter(function(o,r,e){return!!(null!=n&&n!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][r]=e)}});\n\/* ]]> *\/\n<\/script>\n\n                <div class='gf_browser_gecko gform_wrapper gform-theme gform-theme--foundation gform-theme--framework gform-theme--orbital' data-form-theme='orbital' data-form-index='0' id='gform_wrapper_1' ><style>#gform_wrapper_1[data-form-index=\"0\"].gform-theme,[data-parent-form=\"1_0\"]{--gf-color-primary: #204ce5;--gf-color-primary-rgb: 32, 76, 229;--gf-color-primary-contrast: #fff;--gf-color-primary-contrast-rgb: 255, 255, 255;--gf-color-primary-darker: #001AB3;--gf-color-primary-lighter: #527EFF;--gf-color-secondary: #fff;--gf-color-secondary-rgb: 255, 255, 255;--gf-color-secondary-contrast: #112337;--gf-color-secondary-contrast-rgb: 17, 35, 55;--gf-color-secondary-darker: #F5F5F5;--gf-color-secondary-lighter: #FFFFFF;--gf-color-out-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-out-ctrl-light-rgb: 17, 35, 55;--gf-color-out-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-out-ctrl-light-lighter: #F5F5F5;--gf-color-out-ctrl-dark: #585e6a;--gf-color-out-ctrl-dark-rgb: 88, 94, 106;--gf-color-out-ctrl-dark-darker: #112337;--gf-color-out-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-color-in-ctrl: #fff;--gf-color-in-ctrl-rgb: 255, 255, 255;--gf-color-in-ctrl-contrast: #112337;--gf-color-in-ctrl-contrast-rgb: 17, 35, 55;--gf-color-in-ctrl-darker: #F5F5F5;--gf-color-in-ctrl-lighter: #FFFFFF;--gf-color-in-ctrl-primary: #204ce5;--gf-color-in-ctrl-primary-rgb: 32, 76, 229;--gf-color-in-ctrl-primary-contrast: #fff;--gf-color-in-ctrl-primary-contrast-rgb: 255, 255, 255;--gf-color-in-ctrl-primary-darker: #001AB3;--gf-color-in-ctrl-primary-lighter: #527EFF;--gf-color-in-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-in-ctrl-light-rgb: 17, 35, 55;--gf-color-in-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-in-ctrl-light-lighter: #F5F5F5;--gf-color-in-ctrl-dark: #585e6a;--gf-color-in-ctrl-dark-rgb: 88, 94, 106;--gf-color-in-ctrl-dark-darker: #112337;--gf-color-in-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-radius: 3px;--gf-font-size-secondary: 14px;--gf-font-size-tertiary: 13px;--gf-icon-ctrl-number: url(\"data:image\/svg+xml,%3Csvg width='8' height='14' viewBox='0 0 8 14' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M4 0C4.26522 5.96046e-08 4.51957 0.105357 4.70711 0.292893L7.70711 3.29289C8.09763 3.68342 8.09763 4.31658 7.70711 4.70711C7.31658 5.09763 6.68342 5.09763 6.29289 4.70711L4 2.41421L1.70711 4.70711C1.31658 5.09763 0.683417 5.09763 0.292893 4.70711C-0.0976311 4.31658 -0.097631 3.68342 0.292893 3.29289L3.29289 0.292893C3.48043 0.105357 3.73478 0 4 0ZM0.292893 9.29289C0.683417 8.90237 1.31658 8.90237 1.70711 9.29289L4 11.5858L6.29289 9.29289C6.68342 8.90237 7.31658 8.90237 7.70711 9.29289C8.09763 9.68342 8.09763 10.3166 7.70711 10.7071L4.70711 13.7071C4.31658 14.0976 3.68342 14.0976 3.29289 13.7071L0.292893 10.7071C-0.0976311 10.3166 -0.0976311 9.68342 0.292893 9.29289Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-select: url(\"data:image\/svg+xml,%3Csvg width='10' height='6' viewBox='0 0 10 6' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M0.292893 0.292893C0.683417 -0.097631 1.31658 -0.097631 1.70711 0.292893L5 3.58579L8.29289 0.292893C8.68342 -0.0976311 9.31658 -0.0976311 9.70711 0.292893C10.0976 0.683417 10.0976 1.31658 9.70711 1.70711L5.70711 5.70711C5.31658 6.09763 4.68342 6.09763 4.29289 5.70711L0.292893 1.70711C-0.0976311 1.31658 -0.0976311 0.683418 0.292893 0.292893Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-search: url(\"data:image\/svg+xml,%3Csvg width='640' height='640' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath d='M256 128c-70.692 0-128 57.308-128 128 0 70.691 57.308 128 128 128 70.691 0 128-57.309 128-128 0-70.692-57.309-128-128-128zM64 256c0-106.039 85.961-192 192-192s192 85.961 192 192c0 41.466-13.146 79.863-35.498 111.248l154.125 154.125c12.496 12.496 12.496 32.758 0 45.254s-32.758 12.496-45.254 0L367.248 412.502C335.862 434.854 297.467 448 256 448c-106.039 0-192-85.962-192-192z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-label-space-y-secondary: var(--gf-label-space-y-md-secondary);--gf-ctrl-border-color: #686e77;--gf-ctrl-size: var(--gf-ctrl-size-md);--gf-ctrl-label-color-primary: #112337;--gf-ctrl-label-color-secondary: #112337;--gf-ctrl-choice-size: var(--gf-ctrl-choice-size-md);--gf-ctrl-checkbox-check-size: var(--gf-ctrl-checkbox-check-size-md);--gf-ctrl-radio-check-size: var(--gf-ctrl-radio-check-size-md);--gf-ctrl-btn-font-size: var(--gf-ctrl-btn-font-size-md);--gf-ctrl-btn-padding-x: var(--gf-ctrl-btn-padding-x-md);--gf-ctrl-btn-size: var(--gf-ctrl-btn-size-md);--gf-ctrl-btn-border-color-secondary: #686e77;--gf-ctrl-file-btn-bg-color-hover: #EBEBEB;--gf-field-img-choice-size: var(--gf-field-img-choice-size-md);--gf-field-img-choice-card-space: var(--gf-field-img-choice-card-space-md);--gf-field-img-choice-check-ind-size: var(--gf-field-img-choice-check-ind-size-md);--gf-field-img-choice-check-ind-icon-size: var(--gf-field-img-choice-check-ind-icon-size-md);--gf-field-pg-steps-number-color: rgba(17, 35, 55, 0.8);}<\/style><div id='gf_1' class='gform_anchor' tabindex='-1'><\/div>\n                        <div class='gform_heading'>\n\t\t\t\t\t\t\t<p class='gform_required_legend'>&quot;<span class=\"gfield_required gfield_required_asterisk\">*<\/span>&quot; indicates required fields<\/p>\n                        <\/div><form method='post' enctype='multipart\/form-data' target='gform_ajax_frame_1' id='gform_1'  action='\/travere-redesign\/wp-json\/wp\/v2\/poster\/5858#gf_1' data-formid='1' novalidate>\n                        <div class='gform-body gform_body'><div id='gform_fields_1' class='gform_fields top_label form_sublabel_above description_below validation_below'><div id=\"field_1_2\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_2'>First Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_2' id='input_1_2' type='text' value='' class='large'    placeholder='First Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_3\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_3'>Last Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_3' id='input_1_3' type='text' value='' class='large'    placeholder='Last Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_1\" class=\"gfield gfield--type-email gfield--input-type-email gfield--width-full gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_1'>Email<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_email'>\n                            <input name='input_1' id='input_1_1' type='email' value='' class='medium'   placeholder='Your Email' aria-required=\"true\" aria-invalid=\"false\"  \/>\n                        <\/div><\/div><div id=\"field_1_4\" class=\"gfield gfield--type-captcha gfield--input-type-captcha gfield--width-full field_sublabel_above gfield--no-description field_description_below field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label screen-reader-text' for='input_1_4'><\/label><div id='input_1_4' class='ginput_container ginput_recaptcha' data-sitekey='6LdC-_4qAAAAAFq7fXBVZpv8VBlO518KAQ92yXpY'  data-theme='light' data-tabindex='-1' data-size='invisible' data-badge='bottomright'><\/div><\/div><\/div><\/div>\n        <div class='gform-footer gform_footer top_label'> <input type='submit' id='gform_submit_button_1' class='gform_button button' onclick='gform.submission.handleButtonClick(this);' data-submission-type='submit' value='Subscribe Now'  \/> <input type='hidden' name='gform_ajax' value='form_id=1&amp;title=&amp;description=&amp;tabindex=0&amp;theme=orbital&amp;styles=[]&amp;hash=19a707562f078a6ce83770354aeb3dd2' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submission_method' data-js='gform_submission_method_1' value='iframe' \/>\n            <input type='hidden' class='gform_hidden' name='gform_theme' data-js='gform_theme_1' id='gform_theme_1' value='orbital' \/>\n            <input type='hidden' class='gform_hidden' name='gform_style_settings' data-js='gform_style_settings_1' id='gform_style_settings_1' value='[]' \/>\n            <input type='hidden' class='gform_hidden' name='is_submit_1' value='1' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submit' value='1' \/>\n            \n            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' \/>\n            <input type='hidden' class='gform_hidden' name='state_1' value='WyJbXSIsIjY5OGM1NmFiMTIxOTFmZGIyYmVmMjY3YTI3NzY4MjVkIl0=' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_target_page_number_1' id='gform_target_page_number_1' value='0' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_source_page_number_1' id='gform_source_page_number_1' value='1' \/>\n            <input type='hidden' name='gform_field_values' value='' \/>\n            \n        <\/div>\n                        <\/form>\n                        <\/div>\n\t\t                <iframe style='display:none;width:0px;height:0px;' src='about:blank' name='gform_ajax_frame_1' id='gform_ajax_frame_1' title='This iframe contains the logic required to handle Ajax powered Gravity Forms.'><\/iframe>\n\t\t                <script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n gform.initializeOnLoaded( function() {gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery('#gform_ajax_frame_1').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_1');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_1').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_1').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_1').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_1').removeClass('gform_validation_error');}setTimeout( function() { \/* delay the scroll by 50 milliseconds to fix a bug in chrome *\/ jQuery(document).scrollTop(jQuery('#gform_wrapper_1').offset().top - mt); }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_1').val();gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery(document).trigger('gform_page_loaded', [1, current_page]);window['gf_submitting_1'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_1').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_1').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [1]);window['gf_submitting_1'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_1').text());}else{jQuery('#gform_1').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger(\"gform_pre_post_render\", [{ formId: \"1\", currentPage: \"current_page\", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( \"gform_wrapper_1\" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( \"span\" );            visibilitySpan.id = \"gform_visibility_test_1\";            gformWrapperDiv.insertAdjacentElement( \"afterend\", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( \"gform_visibility_test_1\" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 1, current_page );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } );} ); \n\/* ]]> *\/\n<\/script>\n\t\t<div class=\"agreement\">\n\t\t\t<div id=\"agreement-box-newsletter\">\n\t\t\t\t<input type=\"checkbox\" id=\"agreement-check-newsletter\" \/>\n\t\t\t\t<label for=\"agreement-check-newsletter\"><\/label>\n\t\t\t\t<div id=\"agreement-box-tick-newsletter\">\n\t\t\t\t\t<span class=\"icon2-tick\"><\/span>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p>I understand that by checking this box and clicking &#8220;Subscribe now&#8221; I am submitting my contact information and I consent to receive company communications from Travere Therapeutics.<\/p>\n\t\t\t\t<p>All personal information will be processed by or on behalf of Travere to provide access to company information and engage in marketing activities. Travere will retain personal information only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal information is private and will not sell this personal information or disseminate it to third parties who are not providing services to Travere. You may unsubscribe at any time. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\" rel=\"noopener\">Travere  privacy policies<\/a>.<\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div id=\"invalid-newsletter\" class=\"invalid\">\n\t\t\t<div id=\"invalid-box-newsletter\">\n\t\t\t\t<span class=\"icon2-info-fill\"><\/span>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p><strong>Invalid email address.<\/strong><br \/>\n\t\t\t\tMake sure email is in correct format: <a href=\"\">name@example.com<\/a><\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center\" id=\"h-related-content\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span class=\"fw-600\">Related Content<\/span><\/mark><\/h4>\n\n\n  <div class=\"carousel-posts poster-carousel swiper carousel-type-poster wp-block-grizzly-posts-carousel\">\n    <div class=\"swiper-wrapper\">\n      <div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Outcomes of the DUPLEX Trial in Patients With Genetic Focal Segmental Glomerulosclerosis (gFSGS)\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Outcomes of the DUPLEX Trial in Patients With Genetic Focal Segmental Glomerulosclerosis (gFSGS)<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/ASN2024_Poster_DUPLEX-gFSGS.pdf\" target=\"_blank\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Learn more: Outcomes of the DUPLEX Trial in Patients With Genetic Focal Segmental Glomerulosclerosis (gFSGS)\">Learn more<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div><div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Health-Related Quality of Life in Adult Patients With Focal Segmental Glomerulosclerosis (FSGS): Sparsentan Versus Irbesartan\u00a0\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Health-Related Quality of Life in Adult Patients With Focal Segmental Glomerulosclerosis (FSGS): Sparsentan Versus Irbesartan\u00a0<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/ASN2024_Poster_DUPLEX-PRO.pdf\" target=\"_blank\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Learn more: Health-Related Quality of Life in Adult Patients With Focal Segmental Glomerulosclerosis (FSGS): Sparsentan Versus Irbesartan\u00a0\">Learn more<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div><div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">FSGS<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2025\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/ERA2025-Poster-DUPLEX-proteinuria-thresholds.pdf\" target=\"_blank\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Learn more: Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX\">Learn more<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div>    <\/div>\n    <div class=\"swiper-pagination\"><\/div>\n          <\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-footnotes\" style=\"margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Footnotes<\/mark><\/span><\/h5>\n\n\n\n<p class=\"has-small-font-size\" style=\"margin-bottom:calc(30px * var(--scale))\">Sparsentan is not FDA approved for the treatment of FSGS.<br><br>*The DUPLEX Study was conducted during the COVID-19 pandemic.<br><br>CI, confidence interval; COVID-19, coronavirus disease of 2019; DEARA, Dual Endothelin Angiotensin Receptor Antagonist; eGFR, estimated glomerular filtration rate; FPRE, FSGS partial remission endpoint; FSGS, focal segmental glomerulosclerosis; TEAE, treatment-emergent adverse event; UPCR, urine protein-creatinine ratio.<\/p>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ol class=\"wp-block-list\">\n<li class=\"has-small-font-size\">Tumlin J et al. Presented at: National Kidney Foundation Spring Clinical Meetings 2025; April 10-13, 2025; Boston, USA. LB-07.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Shabaka A et al.<em> Nephron<\/em>. 2020;144(9):413-427.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. <em>Kidney Int<\/em>. 2021;100(4S):S1-S276.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Mathias SD et al. <em>Am J Kidney Dis<\/em>. 2017;70(4):532-540.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Szklarzewicz J et al. Poster presented at: European Renal Association Congress 2023; June 15-18. 2023; Milan, Italy.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Bensink ME et al. <em>Kidney Med<\/em>. 2024;6(2):100760.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Cravedi P et al. <em>Am J Transplant<\/em>. 2013;13(2):266-274.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Pitcher D et al. Poster presented at: European Renal Association Congress 2023; June 15-18. 2023; Milan, Italy.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Gipson DS et al. <em>JAMA Netw Open<\/em>. 2022;5(8):e2228701.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Smith A. Poster presented at: American Society of Nephrology Kidney Week 2024. October 24-27, 2024. San Diego, CA.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kohan DE et al. <em>Clin Sci (Lond)<\/em>. 2024;138(11):645-662.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Rheault MN et al.<em> N Engl J Med<\/em>. 2023;389(26):2436-2445.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Trachtman H et al. <em>Kidney International Reports<\/em>. 2023;8(10):2017-2028.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Trachtman H <em>Expert Opin Emerg Drugs<\/em>. 2020;25(3):367-375.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Trachtman H et al. <em>J Am Soc Nephrol<\/em>. 2018;29(11):2745-2754.<\/li>\n<\/ol>\n<\/div>\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-right\" style=\"margin-top:calc(30px * var(--scale));margin-bottom:calc(300px * var(--scale))\"><br>MA-SP-25-0054 | July 2025<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\n<p><\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":"","pdf_file_link":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/04\/NKF2025_Poster_DUPLEX-FSGS-Thresholds.pdf"},"product":[78],"therapeutic_area":[97],"disease_area":[186],"study_registry":[187],"study_type":[176],"resource_type":[199,200,180],"class_list":["post-5858","poster","type-poster","status-publish","hentry","product-spa","therapeutic_area-neph","disease_area-fsgs","study_registry-duplex","study_type-clinical","resource_type-poster","resource_type-presentation","resource_type-summary"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sparsentan Improves Proteinuria in Focal Segmental Glomerulosclerosis<\/title>\n<meta name=\"description\" content=\"Learn more about partial and complete remission of proteinuria in patients with FSGS in the DUPLEX trial. Read now.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)\" \/>\n<meta property=\"og:description\" content=\"Learn more about partial and complete remission of proteinuria in patients with FSGS in the DUPLEX trial. Read now.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/posters\/duplex-proteinuria-remission-fsgs\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T06:34:09+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/duplex-proteinuria-remission-fsgs\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/duplex-proteinuria-remission-fsgs\\\/\",\"name\":\"Sparsentan Improves Proteinuria in Focal Segmental Glomerulosclerosis\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"datePublished\":\"2025-05-08T14:39:47+00:00\",\"dateModified\":\"2025-10-15T06:34:09+00:00\",\"description\":\"Learn more about partial and complete remission of proteinuria in patients with FSGS in the DUPLEX trial. Read now.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/duplex-proteinuria-remission-fsgs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/duplex-proteinuria-remission-fsgs\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/duplex-proteinuria-remission-fsgs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DUPLEX Study: Proteinuria Reduction in FSGS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sparsentan Improves Proteinuria in Focal Segmental Glomerulosclerosis","description":"Learn more about partial and complete remission of proteinuria in patients with FSGS in the DUPLEX trial. Read now.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)","og_description":"Learn more about partial and complete remission of proteinuria in patients with FSGS in the DUPLEX trial. Read now.","og_url":"https:\/\/clleancode.top\/travere-redesign\/posters\/duplex-proteinuria-remission-fsgs\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-10-15T06:34:09+00:00","twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/duplex-proteinuria-remission-fsgs\/","url":"https:\/\/clleancode.top\/travere-redesign\/posters\/duplex-proteinuria-remission-fsgs\/","name":"Sparsentan Improves Proteinuria in Focal Segmental Glomerulosclerosis","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"datePublished":"2025-05-08T14:39:47+00:00","dateModified":"2025-10-15T06:34:09+00:00","description":"Learn more about partial and complete remission of proteinuria in patients with FSGS in the DUPLEX trial. Read now.","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/duplex-proteinuria-remission-fsgs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/posters\/duplex-proteinuria-remission-fsgs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/duplex-proteinuria-remission-fsgs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"DUPLEX Study: Proteinuria Reduction in FSGS"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 13:00:01","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"product","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/poster\/5858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/poster"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=5858"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=5858"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=5858"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=5858"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=5858"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=5858"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=5858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}